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Abstract 
Rationale 
Thyroid hormones and their interactions with catecholamines play a potentially important role in 
alterations of mood and cognition.  
Objectives 
This study aimed to examine the neurobiological effects of catecholamine depletion on thyroid hormones 
by measuring endocrine and cerebral metabolic function in unmedicated subjects with remitted MDD 
(RMDD) and in healthy controls.  
Methods 
This was a randomized, placebo-controlled, and double-blind crossover trial that included 15 unmedicated 
RMDD subjects and 13 healthy control subjects. The participants underwent two 3-day-long sessions at 
1-week intervals; each participant was randomly administered oral α-methyl-para-tyrosine (AMPT) in one 
session (catecholamine depletion) and an identical capsule containing hydrous lactose (sham depletion) in 
the other session prior to a [18F]-fluorodeoxyglucose positron emission tomography scan (18FDG-PET). 
Results 
Serum concentrations of free T3 (FT3), free T4 (FT4), and TSH were obtained and assessed with respect 
to their relationship to regional cerebral glucose metabolism. Both serum FT3 (P = 0.002) and FT4 (P = 
0.0009) levels were less suppressed after catecholamine depletion compared with placebo treatment in the 
entire study sample. There was a positive association between both FT3 (P = 0.0005) and FT4 (P = 
0.002) and depressive symptoms measured using the MADRS. The relative elevation in FT3 level was 
correlated with a decrease in regional glucose metabolism in the right dorsolateral prefrontal cortex 
(rDLPFC; P < 0.05, corrected).  
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Conclusions 
This study provided evidence of an association between a thyroid-catecholamine interaction and mood 
regulation in the rDLPFC. 
 
Key words: triiodothyronine; PET; thyroid; depression; catecholamines; dorsolateral prefrontal cortex 
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Introduction 
The association between thyroid function, brain metabolism, and mood has drawn increasing attention in 
recent years within the clinical neuroscience literature. With improvements in neuroimaging techniques, 
some insights have been gained into the effects of thyroid hormones on the central nervous system, and it 
is now well established that these hormones modulate a variety of cerebral functions that are involved in 
mood and cognition (Bauer et al. 2008). Notably, research suggests that mood disorders, cognitive 
impairment, and other psychiatric symptoms may arise even in subjects with subclinically disturbed 
thyroid function (Zhu et al. 2006). Patients with manifest thyroid disorders have been shown to have a 
higher disposition to the development of depressive symptoms (Hendrick et al. 1998), including anxiety 
induced by hyperthyroidism (Kathol and Delahunt 1986). Conversely, depression may be accompanied by 
various subtle thyroid abnormalities. Relatively few previous functional neuroimaging studies have 
investigated the neural correlates of mood dysfunction in patients with hypothyroidism (Bauer et al. 2009; 
Constant et al. 2001; Nagamachi et al. 2004; Schraml et al. 2006; Zhu et al. 2006), and these studies 
reported cerebral hypoperfusion as the most consistent finding (Bauer et al. 2009; Constant et al. 2001; 
Forchetti et al. 1997; Kinuya et al. 1999; Krausz et al. 2007; Krausz et al. 2004; Nagamachi et al. 2004; 
Schraml et al. 2006). In a subgroup of patients, this hypoperfusion subsided after thyroid replacement 
therapy (Bauer et al. 2009). Thus, the mechanisms underlying the interactions between thyroid function, 
brain metabolism, and mood remain to be clarified. 
The study of the interactions between thyroid hormones and catecholamines is a promising approach to 
the elucidation of the relationship between central thyroid function and mood. The clinical symptoms of 
sympathetic overactivity and hyperthyroidism are strikingly similar, and the similarities between the 
physiological effects of thyroid hormones and catecholamines suggest interactions at both peripheral and 
central receptor sites (Harrison 1964; Waldstein 1966). At the latter sites, such interactions might explain 
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the augmentation effects of thyroid hormones in patients with major depression (MDD) who are treated 
with monoaminergic antidepressants (Bauer and Whybrow 2001).  
The experimental paradigm of catecholamine depletion affords a relatively direct way to investigate 
thyroid-catecholamine interactions in humans (Hasler et al. 2008). This condition can be induced by 
administering α-methyl-para-tyrosine (AMPT), which is a competitive inhibitor of the rate-limiting 
enzyme in catecholamine synthesis, tyrosine hydroxylase (Nagatsu et al. 1964), and decreases 
catecholamine transmission by depleting central dopamine and norepinephrine stores (Stine et al. 1997; 
Verhoeff et al. 2003). We have reported previously that decreased catecholaminergic neurotransmission 
was associated with increased depressive and anhedonic symptoms and with elevated activity in the 
limbic-cortical-striatal-pallidal-thalamic circuitry (Hasler et al. 2008). Here, we examined the same study 
population with respect to the neurobiological effects of catecholamine depletion on thyroid hormones. 
To avoid a medication bias, we studied unmedicated subjects with remitted MDD (RMDD) and healthy 
controls to measure endocrine and cerebral metabolic function. We used the free T3 (FT3), free T4 (FT4), 
and TSH serum concentrations and the positron emission tomography [18F]-fluorodeoxyglucose (PET-
18FDG) technique to assess the relationships between neurochemistry, neurophysiology, and the level of 
depression measured using the Montgomery-Åsberg Rating Scale of Depression (MADRS). Because of 
the conflicting results regarding the relationship between thyroid hormones and depression (Joffe 1993), 
we based our hypotheses on relatively solid endocrinological data linking catecholamines to thyroid 
hormones. Since dopaminergic transmission inhibits TSH secretion (Kaptein et al. 1980), and 
catecholamines block the TSH-induced stimulation of thyroid cells in vitro (Maayan 1990; Oda et al. 
1991), we hypothesized that catecholamine depletion results in higher serum TSH and thyroid hormone 
levels compared with placebo treatment. In addition, we expected that even small effects of 
catecholamine depletion on thyroid hormones, within the euthyroid state, would suffice to induce 
clinically relevant mood effects since the brain seems to be sensitive to small changes in thyroid hormone 
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levels (Joffe 1993; Meyer and Hesch 1983; Schueler et al. 1990; Yamada and Wilber 1990). Given that 
only a few imaging findings are available that have linked thyroid hormones and brain metabolism, and 
given that these findings were derived from patients with hypothyroidism who often showed depressive 
symptoms as a side effect of their illness rather than from patients with true MDD, any hypothesis 
formulated on the relationship between thyroid hormones, catecholamines, and brain metabolism in 
patients with remitted MDD may at best be viewed as preliminary. As the cerebral AMPT main effect 
was an increase in metabolism in the bilateral anteroventral striatum (AVS) (Hasler et al. 2008), we 
hypothesized that this region of interest (ROI) is associated with alterations in thyroid hormone levels. 
Given the wide distribution of catecholaminergic systems and thyroid hormone receptors throughout the 
brain (Ruel et al. 1985; Schwartz and Oppenheimer 1978), and furthermore, given that thyroid hormones 
appear to regulate central noradrenergic neurotransmission with T3 possibly acting as a co-transmitter 
with norepinephrine within the adrenergic receptor system (Gordon et al. 1999), we applied an additional 
whole-brain analysis in an exploratory fashion. 
Experimental Procedures 
Participants 
We used the data from the study sample that was described in previous studies (Hasler et al. 2008; Hasler 
et al. 2009; Meyers et al. 2011). The experimental group comprised individuals who were aged 18-56 
years and who met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) 
criteria for MDD in full remission (RMDD). The healthy controls had no history of any psychiatric 
disorders and no major psychiatric disorders in first-degree relatives. Diagnosis was established by the 
Structured Clinical Interview for DSM-IV and confirmed via an unstructured interview with a 
psychiatrist. The subjects were recruited through the outpatient clinical services of the National Institutes 
of Mental Health and by advertisements placed in local newspapers and posters placed on the National 
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Institutes of Health campus. Exclusion criteria included major medical illnesses, pregnancy, psychotropic 
drug exposure (including nicotine) within the previous 3 months, substance abuse within the previous 
year, a lifetime history of substance dependence, psychiatric disorders other than MDD, and structural 
brain abnormalities that were observed using magnetic resonance imaging (MRI). Inclusion criteria 
required that RMDD subjects had remained in remission without medications for at least 3 months and 
had manifested an onset of depression before 40 years of age. Written informed consent was obtained, as 
approved by the institutional review board of the National Institute of Mental Health. 
Experimental design 
Using a randomized, double-blind, and placebo-controlled crossover design, subjects underwent 2 
identical sessions that were separated by at least 1 week, in which they received either a body-weight-
adjusted AMPT dose or a placebo (see (Hasler et al. 2008) for details). To reduce the risk of adverse 
reactions, a body-weight-adjusted AMPT dose of 40 mg/kg of body weight was administered orally, up to 
a maximum dose of 4 g, over 22 h. Sham depletion used identical capsules containing hydrous lactose. 
Each session lasted 3 days and was performed on an inpatient basis at the National Institutes of Health 
Clinical Center. To reduce the risk of crystalluria during AMPT administration, subjects were given 
sodium bicarbonate, drank at least 2 L of water daily, and underwent urinalysis twice daily. Behavioral 
ratings included the MADRS and the Beck Anxiety Inventory (BAI). Venous blood was sampled before 
and 24, 36, and 48 h after the administration of the first AMPT dose in each session, to measure serum 
FT3, FT4, and TSH levels using an electrochemiluminescent immunoassay (Boehringer Ingelheim 
Pharma GmbH & Co., KG, Ingelheim, Germany). 
PET imaging 
The PET imaging methods have been described in detail in our previous report using the same participant 
cohort (Hasler et al. 2008). Briefly, the PET images were acquired 30 h after the administration of the 
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first AMPT/placebo dose, which corresponded to the period when peak behavioral responses were 
expected (Berman et al. 1999). Scanning was performed using a GE Advance scanner in 3-dimensional 
mode (35 contiguous slices, 4.25 mm thickness; 3-dimensional resolution = 6 mm full-width at half-
maximum; GE Healthcare, Waukesha, WI, USA) and a slow bolus (over 2 min) injection of 18FDG. To 
obviate the need for arterial blood sampling, cerebral glucose utilization was quantified using a method 
that combines the left ventricular chamber time-tissue radioactivity data that were measured via dynamic 
PET imaging of the heart with venous blood sampling, to provide 18FDG input function (Moore et al. 
2003). This method has been validated previously by comparing it to more invasive approaches that use 
arterial plasma sampling (Moore et al. 2003). During image processing, the left ventricular time-
radioactivity curve was extended in time to include the time of the brain emission scan by obtaining 
venous blood samples 25, 30, 35, and 50 min after 18FDG injection. The mean radioactivity of these 
samples was divided by the mean left ventricular radioactivity concentration registered between 25 and 35 
min postinjection. This ratio was used to scale the 50 min venous sample concentration, which then was 
appended to the left ventricular curve to complete the input function that was used to generate parametric 
images of the regional cerebral metabolic rates for glucose (rCMRglu), as described by Moore and 
colleagues (Moore et al. 2003). To provide an anatomical framework for the analysis of the PET images, 
structural MRI scans were acquired using a 3.0-T scanner. 
PET image analysis 
To assess the correlations between AMPT-induced thyroid alterations and AMPT-induced metabolic 
changes across the whole brain, a voxel-wise analysis of the PET data was performed using MATLAB 
(MATLAB version 8, release 14; The MathWorks, Inc., Natick, MA, USA), SPM8 (Wellcome Trust 
Centre for Imaging, London, England; www.fil.ion.ucl.ac.uk/spm8), and the toolbox aslm (Homan et al. 
2012). PET images were coregistered to the MR images and spatially normalized to the Montreal 
Neurological Institute brain template using SPM8. Images were filtered with a 6 mm Gaussian smoothing 
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kernel to compensate for anatomical variability and misalignment errors that might have arisen during 
spatial normalization. The statistical models that were used to compare the normalized rCMRglu included 
the main effects of placebo vs. drug, subject, and the differences in the serum levels of FT3, FT4, and 
TSH. To account for differences in baseline levels, the differences in thyroid hormone levels were 
calculated between the third time point (which coincides approximately with FDG scanning and the peak 
depressive responses (Hasler et al. 2008)) and the first time point (baseline). We reported clusters with a 
voxel-level threshold of P < 0.05, whole-brain corrected for family-wise error. 
Statistical analyses 
Full factorial linear mixed models with restricted maximum likelihood estimations were used to examine 
the effects of various outcome measures. Schwarz’s Bayesian criteria were used to determine the best 
fitting covariance structure for each set of measures in cases in which the typical compound symmetry 
approach used by ANOVA did not provide the optimal structure for the extant data. The effects of drug, 
diagnosis, and time on FT3, FT4, and TSH levels were assessed using linear mixed models with a first-
order autoregressive covariance structure. The effects of treatment, diagnosis, and time on MADRS and 
BAI scores were assessed using linear mixed models with an autoregressive covariance structure. 
Additional models of the MADRS scores were calculated to include FT3, FT4, or TSH levels as 
additional fixed effects, to assess the influence of thyroid hormones on depressive symptoms. Subject 
number and treatment sequence were included as random effects in all models. Post hoc t tests involved a 
Tukey correction for multiple comparisons. The significance thresholds for these contrasts were set at a 2-
tailed alpha = 0.05. SAS 9.2 (SAS Institute Inc., Cary, NC, USA) was used for all analyses. The means of 
the data are reported, with their associated standard deviations. 
Results 
The clinical and demographic characteristics of the subject samples are detailed in Table 1. 
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Behavioral results 
Fifteen subjects with RMDD and 13 healthy controls were included in the study. The 13 healthy 
volunteers (12 females; mean age ± standard deviation (SD) = 39 ± 12 years) were not significantly 
different from the 15 RMDD subjects (14 females; mean age ± SD = 39 ± 11 years) regarding sex ratio 
and mean age. The mean ratings of mood and anxiety symptoms, sleepiness, and akathisia for each 
treatment condition and group, as well as the course of rebound hypomanic symptoms (which were 
classified according to treatment and group), have been reported previously (Hasler et al. 2008; Hasler et 
al. 2009; Meyers et al. 2011). In addition, serum prolactin levels were increased following catecholamine 
depletion (F[1, 203] = 81.79, P < 0.0001), and no effect of diagnosis (P = 0.58) or treatment-by-diagnosis 
interaction (P = 0.97) was evident. There was no effect of session order (i.e., whether the AMPT or 
placebo session occurred first) on thyroid hormone levels, and no treatment-by-session interaction was 
evident, suggesting that no carry-over effects were present. Consequently, the endocrinologic data of both 
sessions were examined further. 
FT3 concentration in serum 
Figure 1A shows the mean FT3 serum concentrations (with standard errors) for the AMPT and placebo 
treatments. Serum FT3 levels showed a time effect across both conditions and groups (F [3, 144] = 43.34, 
P < 0.0001) that was attributable to a suppression at 36 hours and a rebound at 48 hours. Compared to 
placebo, serum FT3 levels were less suppressed after AMPT administration in both the RMDD and 
control samples (F [1, 79.5] = 10.62, P = 0.002). No effect of diagnosis or treatment-by-diagnosis 
interaction was evident (P = 0.4 and P = 0.8, respectively). The mean FT3 levels (differences between 
FT3 at t = 3 and FT3 at baseline under AMPT treatment minus the same difference under placebo 
treatment) were 0.47 ± 0.66 (range, −0.3 to 2.1) and 0.39 ± 0.69 (range, −0.7 to 1.8) in RMDD patients 
and controls, respectively (t [26] = −0.29, P = 0.77). To examine the effects of FT3 on depressive 
symptoms, FT3 was included as an additional fixed effect in the modeling of the MADRS and BAI 
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responses. We observed a positive association between FT3 levels and depressive symptoms measured 
using the MADRS (F [1, 85.5] = 12.97, P = 0.0005). No association was found between FT3 levels and 
anxiety symptoms measured using the BAI (P = 0.28). 
FT4 concentration in serum 
Figure 1B shows the mean FT4 serum concentrations (with standard errors) for the AMPT and placebo 
treatments. Serum FT4 levels showed a time effect (F [3, 149] = 12.61, P < 0.0001) that was attributable 
to a suppression at 36 hours and a rebound at 48 hours. Compared to placebo, serum FT4 levels were less 
suppressed after AMPT administration in both the RMDD and control samples (F [1, 66] = 12.2, P = 
0.0009). No diagnosis effect (P = 0.3) or treatment-by-diagnosis interaction (P = 0.4) was evident. The 
mean FT4 levels (differences between FT4 at t = 3 and FT4 at baseline under AMPT treatment minus 
the same difference under placebo treatment) were 0.95 ± 1.02 (range, −0.3 to 2.9) and 1.75 ± 1.35 
(range, −0.2 to 4.1) in RMDD patients and controls, respectively (t [25] = 1.76, P = 0.09). To examine the 
effects of FT4 on depressive symptoms, FT4 was included as an additional fixed effect in the modeling of 
the MADRS and BAI responses. We observed a positive association between FT4 levels and depressive 
symptoms measured using the MADRS (F [1, 57] = 9.89, P = 0.003). No association was found between 
FT4 levels and anxiety symptoms measured using the BAI (P = 0.66). 
TSH concentration in serum 
Figure 1C shows the mean TSH serum concentrations (with standard errors) for the AMPT and placebo 
treatments. There was a time effect in serum TSH concentrations (F [3, 151] = 41.88, P < 0.0001) that 
was attributable to a suppression at 36 hours and a rebound at 48 hours across groups and conditions. 
Catecholamine depletion had no treatment effect (P = 0.4) and no diagnosis effect (P = 0.8) on serum 
TSH concentrations. Further, no treatment-by-diagnosis interaction was evident (P = 0.7). There was no 
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association between TSH levels and depressive symptoms measured using the MADRS (P = 0.5) or 
anxiety symptoms measured using the BAI (P = 0.43). 
Correlations between regional cerebral metabolism and thyroid hormone serum concentration 
Whole-brain metabolism did not differ significantly between the groups at baseline or between the 
placebo and AMPT conditions (P > 0.25 for the main effect of group, the main effect of treatment, and 
group-by-treatment interactions). Thus, the analyses were performed using globally normalized data, to 
reduce the variability that was introduced by nonspecific fluctuations in whole-brain activity. In addition, 
in the absence of effects of diagnosis and treatment-by-diagnosis on FT3, FT4, and TSH levels, we 
pooled the data of both groups to perform the analysis. The ROI analysis showed that the AMPT-induced 
elevation in brain metabolism in the AVS did not correlate with the relative elevation in serum FT3 levels 
(P = 0.33). The additional whole-brain analysis revealed that changes in serum FT3 levels correlated 
negatively with metabolic changes in the right inferior frontal gyrus (Brodmann area 46), which is part of 
the right dorsolateral prefrontal cortex (rDLPFC; peak coordinates x, y, z: 54, 28, 12; cluster size: 102 
voxels; t = 6.25, P < 0.05, whole-brain corrected for family-wise error; Figure 2). No other cluster in the 
brain survived a correction for family-wise error, and no regions were identified that exhibited positive 
correlations between metabolic changes and changes in serum FT3 levels. In addition, a correlational 
analysis using serum FT4 or TSH level changes as covariates did not reveal any significant regions after 
applying corrections for multiple testing. 
Discussion 
This study compared the effects of catecholamine depletion on thyroid hormones and brain metabolism. 
The serum FT3 and FT4 concentrations were higher after catecholamine depletion than they were after 
placebo treatment in subjects with RMDD and in healthy controls. A significant correlation between an 
AMPT-induced relative elevation of FT3 level and a corresponding decrease in brain metabolism was 
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found in the rDLPFC. There was a positive association between both serum FT3 and FT4 levels and 
depressive symptoms measured using the MADRS. 
Regardless of treatment, we observed a suppression of TSH, FT3 and FT4 serum levels at 36 hours and a 
rebound at 48 hours which is difficult to interpret. Possibly, the stress of the study procedures (blood-
drawing, lying in the scanner) has contributed to this hormone suppression. We used catecholamine 
depletion with AMPT to study the well-known relationship between thyroid hormones and the 
sympathetic nervous system function (Harrison 1964). Hyperthyroidism bears a resemblance to 
sympathetic overactivity because of the physiological effects that are shared by thyroid hormones and 
catecholamines. In addition, they interact synergistically, and the effects of catecholamines are 
exaggerated by excess thyroid hormones and attenuated by thyroid hormone deficiencies (Waldstein 
1966). Therefore, catecholamine depletion was previously considered a possible therapy for 
hyperthyroidism (Canary et al. 1957), before it was found that it caused a high incidence of mental 
depression as a side effect (Buchanan et al. 1959). Consistent with our a priori hypothesis, serum FT3 and 
FT4 levels were less suppressed under AMPT than they were under placebo treatment in the whole 
sample. Previous research has suggested that catecholamines block the TSH-induced stimulation of 
thyroid cells in vitro (Maayan 1990; Oda et al. 1991). Thus, the relative elevations in FT3 and FT4 levels 
observed might be attributable to decreased catecholaminergic neurotransmission.  
Our finding that serum FT3 and FT4 levels were less suppressed under AMPT is consistent with the 
hypothesis linking thyroid hormones and depressive symptoms. This hypothesis was first proposed by 
Bauer and Whybrow (Bauer 1988) and suggests that the increased FT4 measures in depression are a 
compensatory response “to maintain affective homeostasis” (Joffe 1993). This assumption is consistent 
with the fact that clinical hypothyroidism is associated with depressive symptoms that subside with 
thyroid replacement therapy (Hendrick et al. 1998), and is further supported by the observation that 
thyroid hormones have proven to be useful as augmentative or accelerating treatments in affective 
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disorders (Bauer et al. 2002). The efficacy of both T3 and T4 has been assessed in the treatment of MDD. 
The majority of studies have assessed the efficacy of T3, and an effect on both the acceleration and the 
augmentation of mostly tricyclic antidepressants by T3 has been shown (Altshuler et al. 2001; Aronson et 
al. 1996). A smaller number of studies have examined the use of T4 and found that the augmentation of 
antidepressant therapy by T4 in supraphysiological doses is effective in roughly 50% of patients with 
treatment-resistant depression (Bauer et al. 2005). Comparatively, a significantly higher response to 
tricyclic antidepressants has been found for T3 (53%) vs. T4 (19%) (Joffe and Singer 1990). However, the 
latter study used low T4 doses, whereas more recent studies used supraphysiological doses (Bauer et al. 
2005). Thus, the relatively elevated levels of FT3 and FT4 found in our study support the hypothesis of a 
compensatory response; this finding is in line with that of an early report that suggested a catecholamine-
thyroid interaction in the central nervous system (Whybrow and Prange 1981). This compensatory 
hypothesis is extended by the suggestion that thyroid hormones compensate for central catecholamine 
deficiency. This extended hypothesis is plausible given that central catecholamines are modulated by 
thyroid hormones. The relatively elevated serum FT4 and FT3 levels observed could then be viewed as an 
insufficient effort to compensate for the decrease in catecholamine levels. This is further supported by our 
finding of an association between subtle alterations in FT3 levels and altered regional brain metabolism. 
Specifically, the relatively elevated FT3 levels observed after catecholamine depletion were negatively 
correlated with a change in regional cerebral metabolism in the rDLPFC. The rDLPFC has been 
implicated in the pathogenesis of depressive symptoms based on various types of evidence (Mayberg 
2003). There is reasonable evidence to suggest that glucose metabolism in the rDLPFC is increased in 
patients with MDD (Mayberg 2003), which may explain why many patients with depression benefit from 
the inhibitory effect of low-frequency transcranial magnetic stimulation (TMS) in this region (Gershon et 
al. 2003), even though the most widely used TMS target region is slightly superior to the cluster identified 
here. Thus, our findings support the suggested involvement of the rDLPFC in the pathogenesis of 
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depressive symptoms and lends to previous results by linking decreased regional glucose metabolism to 
relatively elevated serum FT3 levels. The decrease in regional metabolism might then be considered a 
compensatory response to the depressive symptoms related to catecholamine deficiency. However, since 
we did not find a difference between subjects with RMDD and controls regarding AMPT-induced 
changes in serum FT3 levels and corresponding changes in regional glucose metabolism in the rDLPFC, 
this finding does not seem to be specific to MDD. 
Another hypothesis, conflicting to the first hypothesis and in contrast to our finding, has linked depressive 
symptoms to an overactive thyroid axis. Most consistently, higher mean FT4 levels have been reported in 
patients with MDD than in subjects with RMDD and healthy controls (Joffe 2006); moreover, these levels 
subsided with effective treatment (Joffe et al. 1996). These increased FT4 levels might contribute to 
depressive symptoms by inducing higher levels of anxiety, as in hyperthyroidism (Kathol and Delahunt 
1986). Thus, it has been hypothesized that the thyroid axis is overactive in MDD (Joffe and Sokolov 
1994). However, our finding of an association between AMPT-induced depressive symptoms and AMPT-
induced relative elevations in thyroid hormone levels was not mediated by a thyroid-hormone-related 
increase in anxiety because we failed to find any association between thyroid hormones and anxiety 
symptoms. 
In contrast with our a priori hypothesis, there was no association between FT3 levels and altered 
metabolism in the AVS, which was the main cerebral AMPT effect reported previously (Hasler et al. 
2008). This finding is consistent with the results of our previous study, which did not find a direct 
relationship between an RMDD diagnosis or AMPT-induced depressive symptoms and AVS metabolism 
(Hasler et al., 2008). Although in our previous study we found that the strongest relationship between 
catecholamine depletion and depressive symptoms was present in the thalamus and the ventromedial 
prefrontal cortex, the results of the present study suggest that the thyroid−catecholamine interaction that 
was associated with mood regulation is located in the rDLPFC. 
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Surprisingly, AMPT did not affect serum TSH levels significantly. Earlier findings have shown that 
dopaminergic transmission inhibits TSH secretion (Kaptein et al. 1980), and later studies have found that 
AMPT can either cause an increase (Plosker et al. 1995) or a decrease in TSH levels, depending on the 
length of administration (Zimmermann et al. 2001). It is possible, however, that an increase in TSH in 
response to catecholamine depletion was offset by a concomitant reduction in TSH release resulting from 
the negative feedback inhibition that was elicited in response to a relative elevation in FT3 and FT4 
levels. 
Our study had several limitations. The relatively small sample of subjects, the oversampling of female 
study participants, and the ability of RMDD subjects to remain in remission without current treatment 
reduced the generalizability of the results. In addition, we were unable to investigate whether the 
catecholamine-depletion-induced effects on FT3 and FT4 levels were mediated via peripheral or central 
receptor effects; consequently, our study did not establish the mechanism via which catecholamine 
depletion leads to an increase in hormone levels. Moreover, we did not measure plasma or urinary 
catecholamine levels to monitor the effect of catecholamine depletion, because there is no consistent 
relationship between central and peripheral catecholamine levels. Instead, we estimated the central AMPT 
effect by measuring serum prolactin levels, which is the standard method for assessing the depth of 
central catecholamine depletion (Hasler et al. 2008; Hasler et al. 2009; Meyers et al. 2011). In addition, it 
is possible that the relative elevation in serum FT3 levels could be due to increased T3 production by 
conversion of T4 to T3 in various peripheral organs, given that catecholamines have been shown to 
modulate the monodeiodination of T4 to the biologically more active T3, and that AMPT can alter this 
process (Ramadan et al., 2011; Silva and Larsen, 1983). Finally, the AMPT effect on serum FT3 and FT4 
levels was relatively subtle, and all subjects remained euthyroid during the study. Thus, one might 
question the clinical significance of these findings. However, it has to be considered that physiological 
doses of thyroid hormones suffice to supplement the effects of antidepressants, suggesting that even 
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subtle thyroid alterations within the euthyroid state are compatible with clinically relevant mood 
alterations. 
In conclusion, this study provided evidence of an association between a thyroid-catecholamine interaction 
and mood regulation in the rDLPFC. 
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Table and Figure legends 
Table 1  
Demographic and clinical characteristics of unmedicated subjects with remitted major depressive disorder 
(RMDD) and healthy controls. f/m, female/male; MADRS, Montgomery-Åsberg Depression Rating 
Scale; NA, not applicable; SD, standard deviation. 
Figure 1  
Mean free T3 (FT3, A), mean free T4 (FT4, B), and mean TSH (C) levels with standard errors in healthy 
control subjects and subjects with remitted major depressive disorder (RMDD) during the course of the 
catecholamine depletion study using alpha-methyl-para-tyrosine (AMPT) and placebo treatments. Serum 
thyroid hormone levels at the third time point, which coincides approximately with fluorodeoxyglucose 
scanning and with peak depressive responses (Hasler et al. 2008), were used in the additional 
correlational analysis of cerebral glucose metabolism. * indicates a significant treatment effect (P < 0.05). 
Figure 2 
Statistical Parametric Mapping (SPM) image sections illustrating areas in which AMPT-induced changes 
in FT3 levels correlated with corresponding changes in regional glucose metabolism in a voxel-wise 
analysis of the combined subject sample (n = 28). The serum FT3 levels for each subject were calculated 
as the difference in the baseline-corrected levels measured at the third time point (which coincides 
approximately with fluorodeoxyglucose scanning and with peak depressive responses (Hasler et al., 
2008)) between the drug and placebo conditions. This reflected the magnitude of the FT3 alterations that 
were induced by catecholamine depletion. The statistical models used to assess changes in normalized 
regional cerebral metabolic rates for glucose (rCMRGlu) included the main effect of drug vs. placebo, the 
main effect of the serum FT3 levels, and the main effect of subject. There was a significant negative 
relationship in the right inferior frontal gyrus (Brodmann area 46), which is part of the right dorsolateral 
prefrontal cortex (peak coordinates x, y, z: 54, 28, 12; cluster size: 102 voxels; t = 6.25, P < 0.05, whole-
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brain corrected for family-wise error). No region was identified in which the changes in metabolism 
correlated positively with the changes in serum FT3 levels. Voxels are displayed on orthogonal planes 
that were determined from an anatomical magnetic resonance (MR) brain image. The figures are depicted 
in neurological orientation. The gray-scale image is a T1 structural MR image that is representative of 
Montreal Neurological Institute space. Positive values of the x, y, and z coordinates approximately 
represent millimeters to the right, anterior, and superior direction relative to the anterior commissure. The 
colored bar indicates voxel t values. Next to the brain slices, the changes in regional metabolism are 
plotted against the changes in serum FT3 levels. There was a negative relationship between AMPT-
induced changes in normalized regional/global cerebral metabolic rates for glucose (rCMRGlu) and the 
corresponding changes in serum FT3 levels (r = −0.78, P < 0.001). The regression line (determined from 
the Pearson correlation coefficient) represents the regression of the data from RMDD and control subjects 
pooled together (n = 28). 
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Table 1 
Characteristic RMDD (n = 15) Controls (n = 13) 
Sex, No. f/m 14/1 12/1 
Age, mean (SD), years 39 (11) 39 (12) 
Age at onset, mean (SD), years 24 (8.3) NA 
Past major depressive episodes, mean (SD), No. 2.7 (1.4) 0 
Time in remission, months 
Mean (SD) 
Range 
 
35 (28) 
7-118 
 
NA 
NA 
First-degree relative(s) with a mood disorder, No. 14 0 
Remote (>1 year ago) history of alcohol abuse, No. 3 1 
History of drug abuse, No. 0 0 
MADRS score at study entry, mean (SD) 2.3 (2.1) 0.5 (1.2) 
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